Autophagy-Related ncRNAs in Pancreatic Cancer.

autophagy circular RNAs long non-coding RNAs miRNAs non-coding RNAs pancreatic tumors

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
13 Dec 2022
Historique:
received: 05 10 2022
revised: 05 12 2022
accepted: 10 12 2022
entrez: 23 12 2022
pubmed: 24 12 2022
medline: 24 12 2022
Statut: epublish

Résumé

Pancreatic cancer (PC) is a malignancy accounting for only 3% of total cancers, but with a low 5-year relative survival rate. Approximately 80% of PC patients are diagnosed at a late stage when the disease has already spread from the primary site. Despite advances in PC treatment, there is an urgently needed for the identification of novel therapeutic strategies for PC, particularly for patients who cannot undergo classical surgery. Autophagy is an evolutionarily conserved process used by cells to adapt to metabolic stress via the degrading or recycling of damaged or unnecessary organelles and cellular components. This process is elevated in PC and, thus, it contributes to the onset, progression, and cancer cell resistance to chemotherapy in pancreatic tumors. Autophagy inhibition has been shown to lead to cancer regression and to increase the sensitivity of pancreatic cells to radiation and chemotherapy. Emerging studies have focused on the roles of non-coding RNAs (ncRNAs), such as miRNAs, long non-coding RNAs, and circular RNAs, in PC development and progression. Furthermore, ncRNAs have been reported as crucial regulators of many biological processes, including autophagy, suggesting that ncRNA-based autophagy targeting methods could be promising novel molecular approaches for specifically reducing autophagic flux, thus improving the management of PC patients. In this review, we briefly summarize the existing studies regarding the role and the regulatory mechanisms of autophagy-related ncRNAs in the context of this cancer.

Identifiants

pubmed: 36558998
pii: ph15121547
doi: 10.3390/ph15121547
pmc: PMC9785627
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Autophagy. 2021 Nov;17(11):3275-3296
pubmed: 33161807
Pancreas. 2021 Feb 1;50(2):227-234
pubmed: 33565800
Mol Cell. 2011 Sep 16;43(6):904-14
pubmed: 21925379
Gastroenterology. 2013 Nov;145(5):1133-1143.e12
pubmed: 23916944
Cell. 2009 Feb 20;136(4):642-55
pubmed: 19239886
N Engl J Med. 2012 Oct 4;367(14):1332-40
pubmed: 23034021
Oncotarget. 2016 Sep 20;7(38):62778-62788
pubmed: 27542202
Pathologica. 2020 Sep;112(3):210-226
pubmed: 33179623
Nat Struct Mol Biol. 2015 Jan;22(1):20-8
pubmed: 25565029
Nature. 2016 Aug 25;536(7617):479-83
pubmed: 27509858
Bone. 2020 Dec;141:115617
pubmed: 32853852
Autophagy. 2014 Sep;10(9):1683-4
pubmed: 25046107
Autophagy. 2017 Apr 3;13(4):703-714
pubmed: 28121485
PLoS One. 2012;7(2):e30733
pubmed: 22319583
Nat Rev Clin Oncol. 2020 Feb;17(2):108-123
pubmed: 31705130
Int J Mol Sci. 2016 Aug 12;17(8):
pubmed: 27529237
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Neural Plast. 2020 Sep 22;2020:8881687
pubmed: 33029125
World J Gastroenterol. 2014 Jul 28;20(28):9354-60
pubmed: 25071330
Am J Transl Res. 2022 Jan 15;14(1):20-54
pubmed: 35173828
Nat Rev Genet. 2008 Nov;9(11):831-42
pubmed: 18852696
Front Cell Dev Biol. 2020 Dec 10;8:602901
pubmed: 33363161
Cancer Res. 2008 Feb 1;68(3):918-26
pubmed: 18245495
Oncotarget. 2016 Nov 1;7(44):71635-71650
pubmed: 27626694
CMAJ. 2013 Oct 1;185(14):1219-26
pubmed: 23610017
Biochem Biophys Res Commun. 2019 Mar 19;510(4):508-514
pubmed: 30737032
Cancer Lett. 2016 Oct 10;381(1):269-77
pubmed: 27461582
Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):172-8
pubmed: 24234587
Biomedicines. 2021 Mar 23;9(3):
pubmed: 33806891
Cell Physiol Biochem. 2018;47(2):747-758
pubmed: 29807360
World J Clin Cases. 2021 May 6;9(13):2969-2982
pubmed: 33969083
Crit Rev Oncol Hematol. 2016 May;101:193-206
pubmed: 27021395
Cells. 2020 Jan 07;9(1):
pubmed: 31936122
Mod Pathol. 2007 Feb;20 Suppl 1:S94-112
pubmed: 17486055
Endocr Relat Cancer. 2019 Aug 1;26(9):R519-R544
pubmed: 31252410
Mol Cancer. 2020 Jul 29;19(1):118
pubmed: 32727463
Int J Biochem Cell Biol. 2019 Jun;111:63-71
pubmed: 30710750
Expert Opin Ther Targets. 2015 Mar;19(3):415-26
pubmed: 25434362
Transl Oncol. 2021 Jul;14(7):101090
pubmed: 33831655
Oncotarget. 2017 Feb 14;8(7):11071-11082
pubmed: 28052003
Front Oncol. 2013 Nov 18;3:282
pubmed: 24303367
Nat Rev Drug Discov. 2021 Aug;20(8):629-651
pubmed: 34145432
Biomaterials. 2019 Feb;192:590-600
pubmed: 30553134
Cancer Drug Resist. 2022 Jun 21;5(3):625-636
pubmed: 36176754
Wiley Interdiscip Rev RNA. 2018 Jul;9(4):e1478
pubmed: 29655315
Cancer Drug Resist. 2020 May 11;3(3):491-520
pubmed: 35582441
Front Pharmacol. 2022 Feb 22;13:837503
pubmed: 35273510
Cell. 1993 Dec 3;75(5):843-54
pubmed: 8252621
Oncol Rep. 2014 Dec;32(6):2485-92
pubmed: 25269958
Mol Cancer. 2021 Mar 9;20(1):51
pubmed: 33750389
Cell. 1993 Dec 3;75(5):855-62
pubmed: 8252622
Front Oncol. 2019 Oct 02;9:1008
pubmed: 31632922
Curr Health Sci J. 2017 Apr-Jun;43(2):132-136
pubmed: 30595868
BMC Med. 2018 Nov 22;16(1):214
pubmed: 30463539
Aging (Albany NY). 2021 Aug 10;13(15):19272-19281
pubmed: 34374662
Genome Biol. 2013 Nov 29;14(11):R131
pubmed: 24289259
Biomed Pharmacother. 2020 Dec;132:110799
pubmed: 33035835
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
Mol Cancer Ther. 2016 Sep;15(9):2232-43
pubmed: 27371730
Acta Radiol. 2016 Mar;57(3):260-70
pubmed: 25855665
Cancer Sci. 2017 Sep;108(9):1811-1819
pubmed: 28677209
Theranostics. 2021 Jan 1;11(6):2755-2769
pubmed: 33456571
Nat Rev Drug Discov. 2013 Nov;12(11):847-65
pubmed: 24172333
Dev Biol. 2009 Feb 1;326(1):4-35
pubmed: 19013144
Mol Cancer. 2015 Oct 12;14:179
pubmed: 26458814
Theranostics. 2020 Jan 1;10(3):1151-1165
pubmed: 31938057
Front Oncol. 2017 Mar 31;7:51
pubmed: 28409123
Int J Mol Sci. 2019 Sep 05;20(18):
pubmed: 31491899
J Transl Med. 2017 Oct 19;15(1):211
pubmed: 29052509
J Clin Invest. 2015 Jan;125(1):42-6
pubmed: 25654549
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D135-9
pubmed: 16381831
Cancer Lett. 2017 Aug 1;400:69-78
pubmed: 28450156
Genes Dev. 2006 May 15;20(10):1218-49
pubmed: 16702400
Prog Mol Biol Transl Sci. 2016;144:241-275
pubmed: 27865459
Bull Cancer. 2021 Mar;108(3):304-322
pubmed: 33423775
Gastroenterology. 2017 Jan;152(1):68-74.e2
pubmed: 27856273
Genet Res (Camb). 2022 May 14;2022:3895396
pubmed: 35645615
Biochem Biophys Res Commun. 2015 Dec 18;468(3):463-70
pubmed: 26271592
J Cell Biol. 2015 Aug 17;210(4):613-27
pubmed: 26261179
Redox Biol. 2015;4:184-92
pubmed: 25590798
Dev Dyn. 2011 Mar;240(3):530-65
pubmed: 21337462
World J Gastroenterol. 2015 Mar 21;21(11):3157-65
pubmed: 25805920
Cell Death Dis. 2022 Mar 14;13(3):233
pubmed: 35288538
Autophagy. 2021 Oct;17(10):3175-3195
pubmed: 32972302
Mol Cell Endocrinol. 2016 Sep 5;432:83-95
pubmed: 26525415
Nat Rev Genet. 2011 Feb;12(2):99-110
pubmed: 21245828
Genes Dev. 2011 Apr 1;25(7):717-29
pubmed: 21406549
HPB (Oxford). 2008;10(5):371-6
pubmed: 18982154
Epigenomics. 2021 Jan;13(2):145-164
pubmed: 33355508
Mol Neurobiol. 2013 Apr;47(2):726-39
pubmed: 23150170
Int J Mol Sci. 2017 Jun 22;18(7):
pubmed: 28640192
Hepatology. 2012 Jun;55(6):1852-62
pubmed: 22234835
J Exp Clin Cancer Res. 2021 Aug 20;40(1):261
pubmed: 34416910
Tumour Biol. 2015 Apr;36(4):2403-7
pubmed: 25481511
Gastroenterology. 2017 May;152(6):1492-1506.e24
pubmed: 28126348
Science. 2018 Mar 23;359(6382):1344-1345
pubmed: 29567702
Oncol Rep. 2015 Sep;34(3):1557-64
pubmed: 26134156
J Clin Oncol. 2008 Oct 1;26(28):4557-62
pubmed: 18824707
Mol Cell Endocrinol. 2019 Aug 1;493:110424
pubmed: 30991076
Gene. 2020 Aug 30;753:144796
pubmed: 32450203
Cancer Lett. 2021 Apr 10;503:174-184
pubmed: 33508384
Exp Mol Med. 2016 Mar 11;48:e219
pubmed: 26964835
Int J Biol Sci. 2020 Jul 19;16(14):2612-2627
pubmed: 32792860
Oncogene. 2013 Oct 17;32(42):5078-88
pubmed: 23208495
J Cell Mol Med. 2021 Jan;25(1):4-14
pubmed: 33216456
Ann Oncol. 2012 Oct;23 Suppl 7:vii33-40
pubmed: 22997452
Int J Mol Sci. 2021 Apr 10;22(8):
pubmed: 33920083
J Cell Sci. 2003 May 1;116(Pt 9):1679-88
pubmed: 12665549
J Clin Oncol. 2020 Aug 5;:JCO2001364
pubmed: 32755482
Cancers (Basel). 2022 Apr 07;14(8):
pubmed: 35454771
Oncol Rep. 2014 Apr;31(4):1715-22
pubmed: 24573489
World J Surg Oncol. 2017 Aug 17;15(1):155
pubmed: 28818070
Front Cell Dev Biol. 2021 Sep 23;9:746714
pubmed: 34631721
Hepatology. 2009 Jan;49(1):116-23
pubmed: 19085911
Nat Rev Clin Oncol. 2010 Mar;7(3):163-72
pubmed: 20101258
Int J Mol Sci. 2021 Sep 28;22(19):
pubmed: 34638805
Dis Markers. 2020 Jun 1;2020:2782101
pubmed: 32566037
Anticancer Res. 2013 Feb;33(2):445-52
pubmed: 23393335
Carcinogenesis. 2019 Mar 12;40(1):61-69
pubmed: 30321299
Exp Biol Med (Maywood). 2017 Jun;242(11):1136-1141
pubmed: 28485684
Gastroenterol Res Pract. 2016;2016:8962321
pubmed: 26941789
J Cell Mol Med. 2020 Feb;24(3):2252-2259
pubmed: 31880394
Front Oncol. 2021 Jul 14;11:691185
pubmed: 34336679
Cell Death Dis. 2022 Feb 4;13(2):114
pubmed: 35121743
Pharmacol Res. 2020 Nov;161:105130
pubmed: 32818653
Lancet. 2011 Apr 2;377(9772):1184-97
pubmed: 21397320
Int J Oncol. 2019 Feb;54(2):600-626
pubmed: 30570107
Cell Death Dis. 2017 Oct 5;8(10):e3073
pubmed: 28981093
Autophagy. 2009 Aug;5(6):816-23
pubmed: 19535919
Exp Mol Pathol. 2020 Feb;112:104330
pubmed: 31712117
Nat Rev Mol Cell Biol. 2007 Nov;8(11):931-7
pubmed: 17712358

Auteurs

Simone Donati (S)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.

Cinzia Aurilia (C)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.

Gaia Palmini (G)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.

Irene Falsetti (I)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.

Teresa Iantomasi (T)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.

Maria Luisa Brandi (ML)

Fondazione Italiana Ricerca sulle Malattie dell'Osso (FIRMO Onlus), 50141 Florence, Italy.

Classifications MeSH